
Clockwork Bio: Seattle AI Profile — Product, Footprint & Verified Record

Verified: November 19, 2026 · Canonical URL: https://tygartmedia.com/clockwork-bio-seattle-wa-ai-profile/

Verified Record Summary: Clockwork Bio (clockworkbio.ai) is an independent Seattle AI biotechnology startup officially announced in March 2026 by former GSK AI and data leaders Shane Lewin and Nick Peterson. Selected for Plug and Play Seattle's Batch 3 accelerator cohort, the company is building a lab-in-the-loop data engine for pre-clinical oncology drug discovery, with no closed institutional funding total or team headcount publicly disclosed.



Field	Verified Record (As of Nov 19, 2026)
Company	Clockwork Bio
Official Website	clockworkbio.ai (distinct from unrelated consultancy clockwork.bio and GPU vendor Clockwork.io)
Washington HQ	Seattle, WA (CEO Shane Lewin based in Seattle; listed as Seattle by Plug and Play and GeekWire)
Other WA Footprint	Plug and Play Seattle workspace access at UW CoMotion Labs (Seattle); Co-founder & CTO Nick Peterson based in San Francisco, CA
Founded	2026 (official launch announced March 2026)
Founders / Leadership	Shane (John) Lewin (Co-founder & CEO), Nick Peterson, PhD (Co-founder & CTO)
Stage	Accelerator / Raising Seed (Plug and Play Seattle Batch 3, March–June 2026)
Announced Funding	Not publicly disclosed
Team Size	Not publicly disclosed
Primary Ecosystem Ties	Plug and Play Seattle (Batch 3 cohort, UW CoMotion Labs access, UW Kane Hall showcase)

What Clockwork Bio Builds

Clockwork Bio is an AI-native biotechnology startup developing a high-throughput, "lab-in-the-loop" data engine intended to automate pre-clinical drug discovery, starting with oncology. In GeekWire's March 23, 2026 cohort report, Plug and Play Seattle summarized the startup as building a data engine for AI-enabled drug discovery by applying artificial intelligence at every step of the Experimental Biology Loop. Its official landing page at clockworkbio.ai states its mission succinctly as "Engineering a world without cancer."

Technically, Clockwork Bio's platform pairs active learning systems with AI-based phenotyping to push cells in vitro into diseased states and back again, generating structured experimental data to map underlying disease biology and surface therapeutic targets at scale. Researchers and investors looking up the company should carefully verify the domain: Seattle's AI drug discovery company operates at clockworkbio.ai, whereas clockwork.bio belongs to an unrelated fractional COO and lab-space infrastructure consultancy (Clockwork Bio LLC) serving Boston, New York, San Diego, San Francisco, and Europe, and Clockwork.io is an unrelated GPU infrastructure software vendor.

Washington Footprint and Leadership

Clockwork Bio is listed as a Seattle company in Plug and Play Seattle's Batch 3 cohort and GeekWire's March 23, 2026 coverage, reflecting Co-founder and CEO Shane (John) Lewin's Seattle base and the company's participation in Plug and Play's Seattle program with office access inside the University of Washington's CoMotion Labs and cohort showcase programming at UW Kane Hall. The founding team spans two West Coast biotech hubs, with Co-founder and CTO Nick Peterson, PhD based in San Francisco, California.

Both co-founders come directly from senior AI and scientific data roles inside pharmaceutical company GSK (GlaxoSmithKline). Prior to launching Clockwork Bio in March 2026, Shane Lewin served as a VP and leader of AI and Machine Learning at GSK, following earlier engineering and product roles at Microsoft, Netflix, and startups, and holds an MS in Computational and Mathematical Engineering from Stanford University. Nick Peterson, PhD is a mathematician and AI/data leader who previously led GSK's internal Onyx discovery data platform.

Products, Users, and Public Traction

Clockwork Bio is building its lab-in-the-loop discovery engine for internal pre-clinical oncology programs and potential biopharmaceutical R&D partners seeking systematic target discovery. Because the company was announced in March 2026, its public technical and commercial footprint remains deliberately compact.

As observed on November 19, 2026, clockworkbio.ai presents a minimal corporate landing page with navigation for Home, Team, and Blog alongside an inquiry email (info@clockworkbio.ai) and a 2026 copyright notice. No named pharmaceutical collaborators, published peer-reviewed benchmarks, clinical asset timelines, or employee headcounts have been publicly disclosed.

Funding, Stage, and Place in Washington's AI Landscape

Clockwork Bio entered Plug and Play Seattle's 12-week Batch 3 accelerator in March 2026 alongside nine other startups (nine of the ten based in Seattle) for a program running through mid-June 2026. Public event and accelerator records place the company in the accelerator / seed-fundraising stage, with no closed institutional funding amount or venture investor syndicate publicly disclosed as of November 19, 2026.

Within Washington's AI landscape, Clockwork Bio extends Seattle's deep computational biology and life-sciences talent pool—anchored around UW, Fred Hutch, and local big-tech ML alumni—into closed-loop wet-lab data generation. Alongside fellow Plug and Play Seattle life-sciences participant Polybiomics (Batch 2), Clockwork Bio reflects growing investor and accelerator focus on proprietary experimental data engines rather than purely in-silico model wrappers.

Verified Primary Sources & Official References

• Clockwork Bio Official Website: https://clockworkbio.ai/

• GeekWire — Plug and Play Seattle Batch 3 Cohort (Mar 23, 2026): https://www.geekwire.com/2026/10-startups-chosen-for-plug-and-plays-third-seattle-area-accelerator-cohort/

• Plug and Play Seattle: https://www.plugandplaytechcenter.com/locations/seattle

Companion Markdown twin: https://tygartmedia.com/wp-content/uploads/2026/11/clockwork-bio-seattle-wa-ai-profile.md (also mirrored at https://tygartmedia.com/clockwork-bio-seattle-wa-ai-profile.md). Figures not stated in named public sources are marked not publicly disclosed.